

LANNETT CO INC
Form 8-K
October 13, 2015

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Date of Report (Date of earliest event reported): **October 13, 2015**

LANNETT COMPANY, INC.

(Exact Name of Registrant as Specified in Its Charter)

Commission File No. **001-31298**

State of Delaware
(State of Incorporation)

23-0787699
(I.R.S. Employer I.D. No.)

9000 State Road

Philadelphia, PA 19136

(215) 333-9000

(Address of principal executive offices and telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 - o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

ITEM 7.01 REGULATION FD DISCLOSURE

In connection with Lannett Company Inc. s (Lannett) pending private financing transaction related to the pending acquisition of Kremers Urban Pharmaceuticals Inc. (KUPI), Lannett anticipates disclosing to prospective financing sources certain historical financial and other information with respect to Lannett and KUPI that has not been previously publicly reported. This information is attached hereto as Exhibits 99.1, 99.2 and 99.3 and incorporated by reference herein.

The information disclosed under this Item 7.01, including Exhibits 99.1, 99.2 and 99.3 and shall not be deemed filed for purposes of Section 18 of the Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits

99.1 Kremers Urban Pharmaceuticals Inc. Business Overview

99.2 Kremers Urban Pharmaceuticals Inc. Management s Discussion and Analysis of Financial Condition and Results of Operations for the six months ending June 30, 2015 and 2014 and the years ending December 31, 2014, 2013 and 2012

99.3 Lannett Company, Inc. and Kremers Urban Pharmaceuticals Inc. key product revenues by period and certain market information

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

LANNETT COMPANY, INC

By: /s/ Arthur P. Bedrosian
Chief Executive Officer
Date: October 13, 2015

EXHIBIT INDEX

| Exhibit: | Description: |
|-----------------|---|
| 99.1 | Kremers Urban Pharmaceuticals Inc. Business Overview |
| 99.2 | Kremers Urban Pharmaceuticals Inc. Management's Discussion and Analysis of Financial Condition and Results of Operations for the six months ending June 30, 2015 and 2014 and the years ending December 31, 2014 and 2013 |
| 99.3 | Lannett Company, Inc. and Kremers Urban Pharmaceuticals Inc. key product revenues by period and certain market information |